Current Edition


Pfizer’s COVID pill Paxlovid gets boost in Britain thanks to spot in national trial

Pfizer’s COVID-19 vaccine and antiviral show little sign of slowing down in the pandemic’s third year. Now, the company’s oral therapy is getting a boost …

Continue Reading →

Myovant, Pfizer’s expansion bid for Myfembree hits a snag at the FDA

Myovant and Pfizer’s endometriosis expansion bid for Myfembree has hit a pothole late in the FDA’s review process. In a letter to the companies, the United States …

Continue Reading →

Pfizer asks hourly staffers to return overpayments in aftermath of vendor’s cyberattack: reports

A little extra cash is always a welcome surprise—until your employer asks you to pay it back, that is. In December, a ransomware attack struck …

Continue Reading →

In a busy month, Pfizer extends recall of blood pressure meds to the UK

Add another country to the recall list for Pfizer’s blood pressure medicines. Monday, the company pulled one lot of Accuretic off shelves in the U.K., continuing …

Continue Reading →

As rivals eye ‘unjustified royalties,’ Pfizer partner sues to defend COVID-19 shot Comirnaty

Pfizer has already reeled in tens of billions of dollars in sales for its COVID-19 shot Comirnaty. Now, one of the New York pharma’s partners says rival …

Continue Reading →

Sprout hopes women will think pink when it comes to treating Hypoactive Sexual Desire Disorder

Pfizer’s Viagra is so much a part of the cultural landscape that, “little blue pill” is often all that’s needed to identify the drug. Not …

Continue Reading →

Pfizer recalls 2nd blood pressure med in a week, again on potential carcinogen fears

Pfizer issued a second round of Canadian recalls this week as the country’s drug regulator continues to weed out meds with an excess of potential …

Continue Reading →

Deciphera details stomach cancer flop against Pfizer’s Sutent, cracking the door open for off-label use

Deciphera Pharmaceuticals recently took a serious hit to its billion-dollar hopeful cancer drug Qinlock. As the company undertakes a round of layoffs to deal with the …

Continue Reading →

Pfizer’s Cibinqo snags FDA approval to challenge Sanofi and Regeneron’s Dupixent in eczema

Look out, Sanofi and Regeneron: Pfizer is on the scene in atopic dermatitis with another blockbuster-to-be. Friday, the FDA approved the New York drugmaker’s oral …

Continue Reading →

JPM 2022: Pfizer bumps Paxlovid production estimate to 120M for this year while also looking to add more capacity

Developing a COVID-19 vaccine at breakneck speed was a monumental achievement for Pfizer and BioNTech. The accompanying manufacturing effort is just as onerous. Similarly, as …

Continue Reading →